 GOSSELIES, Belgium and LONDON, June 14, 2021 GLOBE NEWSWIRE -- iTeos Therapeutics NASD: ITOS and GlaxoSmithKline plc LSENYSE: GSK today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial. With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG. 